[A18-72] Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2019
Commission awarded on 29.10.2018 by the Federal Joint Committee (G-BA).
Women with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Initial endocrine therapy in postmenopausal women: indication of lesser benefit in comparison with appropriate comparator therapy. Subsequent endocrine therapy and/or pre- or perimenopausal women: added benefit not proven due to a lack of study data.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-32||Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A19-24||Abemaciclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A18-72||Commission completed|
|A18-73||Abemaciclib in combination with fulvestrant (breast cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|